Introduction
The human BRCA2 gene has several high penetrance alleles that predispose to early onset breast cancer (Ponder et al., 2000; Welcsh and King 2001) . The human BRCA2 protein (hBRCA2) is involved in recombination-mediated DNA repair (Baumann et al., 1996) but the mechanism that regulates this activity remains poorly described. The hBRCA2 protein is a large protein (3418 amino acids), whose sequence contains few clues regarding its function. One notable feature, however, is a cluster of eight BRC repeat sequences encoded by exon 11. These repeats are highly conserved between mammalian species (Bork et al., 1996) and are involved in the interaction between hBRCA2 and Rad51 (Wong et al., 1997) , a RecA-like protein required for recombination and DNA repair (Baumann et al., 1996) . Like RecA, Rad51 can form a nucleoprotein filament in association with single-stranded DNA (ssDNA) and catalyse the pairing and subsequent exchange of ssDNA with homologous double-stranded DNA (dsDNA). In addition to its role in DNA repair by homologous recombination (HRR) and in replication fork maintenance, as indicated by the hypersensitivity of hBRCA2-defective cells to DNA damaging agents, hBRCA2 is also implicated in cell cycle regulation, chromatin remodeling and in the regulation of transcription (Venkitaraman, 2000) . In contrast to BRCA1, however, the absence of hBRCA2 appears not to produce defects in either nonhomologous end-joining (NHEJ) or in regulation of cell cycle checkpoints (Yu et al., 2000; Xia et al., 2001) .
One mechanism by which hBRCA2 may contribute to homology-mediated DNA repair is by controlling how Rad51 interacts with two separate hBRCA2 domains following DNA damage, thereby regulating Rad51 (Baumann et al., 1996; Moynahan et al., 2001) . The Rad51-dependent activities that are required to resolve sites of arrested replication must reconcile two divergent sets of observations. On one hand, Rad51 must selfassemble into an active nucleoprotein intermediate at sites of DNA damage to facilitate recombinationmediated reactions, a process for which hBRCA2 is thought to be essential (Baumann et al., 1996; Davies et al., 2001; Moynahan et al., 2001) . On the other hand, there is biochemical and cell biological evidence to suggest that hBRCA2 suppresses Rad51 self-assembly (Pellegrini et al., 2002) . Indeed, recent structural analyses clearly show that the BRC repeats prevent Rad51 oligomerization by interfering with a critical contact between Rad51 subunits (Pellegrini et al., 2002) . These disparate observations have been reconciled in a hypothetical model in which the hBRCA2-Rad51 complex responds to damage-activated signals by shuttling between inactive and active states (Venkitaraman, 2002) . In the inactive state, the hBRCA2-Rad51 complex would sequester Rad51 in a form that is incapable of self-assembly. Activation of the hBRCA2-Rad51 complex by replication arrest or DNA damage would mobilize it at sites where its component proteins would participate in recombination reactions.
In addition to interacting with the BRC repeats encoded by exon 11, Rad51 associates with hBRCA2 residues encoded by exon 27 near the carboxy terminus (Sharan et al., 1997) . Recent evidence shows that the carboxy-terminal region of hBRCA2 contains a site that is phosphorylated on serine 3291 (S3291) by CDK1. Phosphorylation of S3291 is low in S phase when recombination is active, but increases as cells progress toward mitosis. Phosphorylation of this residue impedes the interactions between Rad51 and the carboxyterminal domain of hBRCA2 (Esashi et al., 2005) .
The DNA damage checkpoint protein Chk1 has also shown to be important for DNA repair by HRR, but the mechanism by which Chk1 regulates this process remains unclear (Sorensen et al., 2005) . In this report we have examined the involvement of the DNA damage checkpoint kinases Chk1 and Chk2 on the interactions between hBRCA2 and Rad51, and therefore on the recruitment of Rad51 to sites of DNA damage following replication block or DNA double strand breaks. Our data show that Chk1 and Chk2 can phosphorylate the same residue in the hBRCA2 carboxy-terminal domain. Mutation of this phosphorylation site interferes with Rad51 release from the carboxy-terminal domain of hBRCA2 in vivo following DNA damage. In UV treated cells, depletion of Chk1 from cells using SiRNA produces a complete loss of Rad51 localization to nuclear foci after replication block. In contrast, cells that express a truncated and nonfunctional form of Chk2 show no obvious defect in Rad51 localization at foci, indicating that Chk1 is more involved in regulating the BRCA2-Rad51 interaction in response to replication block. The Chk2-deficient cells show a clear impairment in Rad51 localization following DNA double strand break as a result of IR treatment.
Results
Chk1 and Chk2 both phosphorylate hBRCA2 C-terminal domain in vitro To determine whether hBRCA2 can serve as a substrate for Chk2 and to circumvent the difficulties related to purification of full length hBRCA2 protein, we constructed several GST-hBRCA2 deletion mutants encompassing the entire protein to test as substrates in an in vitro kinase reaction (Figure 1a) . The only fragment of hBRCA2 that was strongly phosphorylated by Chk2 is the C-terminal domain encoded by exons 26 and 27 (Figure 1b ), which contains a Chk2 consensus phosphorylation site. This consensus site is very similar to the well-established Chk2 phosphorylation site at serine 123 of Cdc25A (Figure 1f ). Since Cdc25A serine 123 is phosphorylated by both Chk1 and Chk2, and since Chk1 is an essential kinase for DNA repair and important for Rad51 recruitment to sites of DNA damage (Sorensen et al., 2005) we asked whether or not hBRCA2-CT can serve also as a Chk1 substrate. As shown in Figure 1c , hBRCA2-CT is effectively phosphorylated by Chk1 in vitro. Site-directed mutagenesis identified threonine 3387 as the target site, since substitution of threonine by alanine at residue 3387 abolished in vitro phosphorylation by Chk1 and Chk2 (Figures 1d and e) .
The hBRCA2-CT domain, which is phosphorylated by Chk1 and Chk2, is essential for Rad51 recruitment to sites of DNA damage Following DNA damage involving dsDNA breaks, proteins that participate in the repair process are recruited to discreet nuclear foci. The involvement of the hBRCA2-CT domain in DNA damage repair is well established. Deletion of this domain in mice leads to hypersensitivity to DNA cross-links, chromosomal instability and reduced life span (Donoho et al., 2003) . The importance of this domain in DNA repair may be due to its role in Rad51 binding and the subsequent localization of Rad51 to sites of damage, which can be visualized as nuclear foci. To explore this possibility, we used mouse embryo fibroblasts (MEFs) derived from mice harboring a hBRCA2 gene lacking both exons 26 and 27 (lex1/lex2 cells) and analysed the effect of this deletion on the recruitment of proteins involved in DNA repair to presumptive sites of DNA damage. Figure 2 (lower right panel) shows that Rad51 in lex1/lex2 cells has an impaired capacity to localize at nuclear foci after treatment with Adriamycin. In contrast, wild-type MEFs treated with Adriamycin displayed Rad51 localization almost exclusively at nuclear foci. In lex1/lex2 cells, Rad51 was diffusely distributed indicating that the domain encoded by exons 26 and 27 is important for recruiting Rad51 to sites of DNA damage.
Rad51 binds to the hBRCA2-CT domain in a DNA damage-dependent manner The carboxy-terminal domain of hBRCA2 interacts with Rad51 (Mizuta et al., 1997) . To assess whether or not Chk2 kinase contributes to the regulation of Rad51 binding to hBRCA2, we made an hBRCA2 carboxyterminal GFP fusion protein encompassing the regions encoded by exons 26 and 27 (BRCA2-CT) and showed that this peptide is sufficient to interact with Rad51 ( Figure 3a ). This interaction, however, only occurs in untreated cells and not in cells that have been challenged with ionizing radiation (Figure 3a , indicated by the asterisk). In contrast, the domain of hBRCA2 encoded by exon 11, that encompasses two BRC repeats (GFP-2R), interacts very strongly with Rad51 independent of exposure to ionizing radiation ( Figure 3a) . Overexpression of GFP-exon 11 appears to be cytotoxic, perhaps due to the depletion of Rad51 and subsequent cell death following accumulation of unrepaired DNA. The apparent reduced level of Rad51 associated with exon 11, with or without ionizing radiation (Figure 3a) , is likely attributable to fewer viable cells. Nevertheless, Rad51 immunoprecipitated from the surviving transfected cells binds to the domain encoded by exon 11 of hBRCA2, independent of exposure to ionizing radiation ( Figure 3a ). This observation suggests that the C-terminal region of hBRCA2 plays a role in the activation of the hBRCA2-Rad51 complex in response to DNA damage. This observation is also supported by our results showing that Rad51 localization to nuclear foci in response to DNA damage is severely compromised in the lex1/lex2 cell line that lacks exons 26 and 27 of BRCA2 (Figure 2 ).
Mutation of hBRCA2-T3387 to alanine prevents release of Rad51 from hBRCA2-CT even in the presence of DNA damage To further characterize the role of phosphorylation by Chk1 and Chk2 in the interaction between hBRCA2 and Rad51, cells were transfected with the T3387A phosphorylation site mutant of GFP-tagged hBRCA2-CT or with wild-type GFP-tagged hBRCA2-CT, GFP-2R and GFP alone as a negative control (Figure 3b) . The transfected cells were treated with ionizing radiation and the GFP fusion proteins were immunoprecipitated using an antibody to GFP. The level of Rad51 interacting with each of the GFP-fusion proteins was determined by western blot using antibody to Rad51. As shown in Figure 3b , GFP by itself failed to bind any Rad51, as expected. GFP-hBRCA2-CT, which binds Rad51 in the absence of challenge, released Rad51 after treatment with IR while GFP-2R retained the capacity to bind Rad51. Interestingly, the T3387A mutant GFPhBRCA2-CT failed to release Rad51 even after IR treatment, indicating that phosphorylation of threonine 3387 may play the role of a binding-release switch depending upon the absence or presence of DNA damage. Such a mechanism, which has previously been described for the binding of Rad51 to hBRCA2 and its release during the cell cycle, appears to be regulated by CDKs that, in the context of cell cycle regulation, phosphorylate a different residue than the one described here (Esashi et al., 2005) . Interestingly, overexpression of the mutant form of BRCA2-CT (T3387A) prevented recruitment of Rad51 to sites of DNA damage after IR treatment, highlighting the role of T3387 phosphorylation in Rad51 localization (Figure 3c ).
Regulation of Rad51-hBRCA2-CT binding and release in response to DNA damage The Chk1 kinase, which is required for HR-mediated repair (Sorensen et al., 2005) , mediates phosphorylation of Rad51 on threonine 307. Cells depleted for Chk1 failed to form Rad51 nuclear foci after exposure to hydroxyurea (Sorensen et al., 2005) . To determine whether Chk1 exerts its effect by regulating the binding and release of Rad51 to and from hBRCA2, we constructed a myc-tagged Rad51 cDNA and its mutant counterpart in which the encoded Chk1-phosphorylation site threonine 307 on Rad51 is mutated to alanine (T307A). Cells were cotransfected with either wild-type myc-Rad51 or mutant T307A myc-Rad51 together with the various GFP-hBRCA2 constructs and treated with UV light. Figure 4 shows that when the GFP-hBRCA2 fragments were immunoprecipitated using an antibody to GFP, GFP-2R and GFP-hBRCA2-CT fragments were able to pull down both wild-type and mutant myctagged Rad51, as well as the endogenous Rad51 protein, in the absence of treatment. In contrast, after UV treatment, the amount of myc-Rad51 wild type still bound to hBRCA2-CT was sharply reduced while the amount of myc-Rad51 mutant bound to hBRCA2-CT remained unchanged. The binding and release of Rad51 to and from GFP-2R was not affected by the T307A mutation. This result demonstrates that Chk1-mediated phosphorylation of Rad51 represents another mechanism by which binding of Rad51 to hBRCA2 and its release is controlled. This tight regulation of hBRCA2-Rad51 interaction reflects the crucial role this complex plays in protecting cells from the consequences of potentially lethal DNA lesions through regulation of homologous recombination-mediated repair.
Chk1 and Chk2 play parallel roles in hBRCA2-CT-Rad51 complex formation In order to determine whether Chk1 and Chk2 have separate or redundant roles in the formation of the hBRCA2-Rad51 complex and the localization of Rad51 to sites of DNA damage in response to replication arrest, we took advantage of MEFs derived from mice lacking Chk2 kinase activity (Bahassi et al., 2007) . The Chk2 allele in these mice is designated Chk2*1100delC and has a single cytosine deletion at position 1100. This deletion produces a frameshift near the carboxy end of Chk2 and a truncated protein due to the generation of a premature stop codon. The variant mRNA is unstable resulting in diminished or absent Chk2 protein. Wildtype MEFs and MEFs homozygous for Chk2*1100delC were transfected with a siRNA vector targeted to Chk1 and irradiated with UV. The vector containing the Chk1 siRNA also expresses GFP, which allows discrimination in the same visual field between cells Figure 2 Rad51 sub-cellular distribution in wild-type and hBRCA2 lex1/lex2 cells in response to Adriamycin ( þ ADR) treatment or its absence (ÀADR). Wild-type (left two panels) and lex1/lex2 deletion mutant cells (right two panels) were treated with ADR or left untreated. Endogenous Rad51 was immunostained using an antibody to Rad51. Pictures were taken using confocal microscopy. Only wild-type þ ADR shows Rad51 mainly at foci. transfected with Chk1 siRNA and those that were not. The efficiency with which Rad51 is recruited to sites of DNA damage was monitored by immunofluorescence using antibody directed to Rad51. Figure 5 shows that cells expressing Chk1 siRNA fail to form nuclear foci containing Rad51 after UV-mediated replication block while neighboring cells that do not express Chk1 siRNA show strong Rad51 focus formation. Cells with wildtype Chk2 or cells homozygous for Chk2*1100delC display normal localization of Rad51at nuclear foci following treatment with replication-blocking agents. While replication blocks ultimately lead to DNA double strand break, it seems that such type of double strand breaks elicits Chk1 activation rather than Chk2 activation. These results indicate that Chk1 is preferentially involved in Rad51 localization to sites of DNA damage following replication block as a result of UV treatment, while Chk2 appears to be involved in the same process following DNA double strand breaks following IR treatment.
Discussion
hBRCA2, a tumor suppressor that manifests predominantly in breast and ovarian cancer, binds to the Rad51protein through eight conserved BRC repeats Figure 3 Rad51 interaction with hBRCA2-CT but not with the domain encoded by exon 11 is dependent on IR treatment. (a) Cells were transfected with GFP-exon 11 (lanes 1 and 2), GFP-2R (lanes 3 and 4), GFP-BRCA-CT (lanes 5 and 6) or GFP alone (lanes 7 and 8) and were either treated with IR ( þ ) or left untreated (À). The GFP fusion proteins were immunoprecipitated from the cell lysates using GFP antibody and analysed by SDS-PAGE followed by western blotting for Rad51 protein. that are motifs comprised of about 30 residues that are dispersed across a large region in the middle of the protein. The BRCA2 protein is essential for homologous recombination in vivo. When introduced into cells, individual BRC repeat peptides act in a dominant negative fashion and prevent the assembly of Rad51 into active nucleoprotein filaments in vitro (Pellegrini et al., 2002) . This observation suggests a model in which BRCA2 sequesters RAD51 in undamaged cells, and facilitates recombination-mediated repair after DNA damage. How BRCA2 carries out these dual functions remains unclear. The carboxy-terminal domain of hBRCA2 interacts directly with the Rad51 protein, contains a nuclear localization signal, and appears to be necessary for maintaining genomic stability in response to various types of DNA damage (Davies et al., 2001; Moynahan et al., 2001) . The interaction between the carboxy terminus of BRCA2 and Rad51 is pivotal for the role BRCA2 plays in the activation of double strand break repair and/or homologous recombination, and disruption of these processes may result in a predisposition to cancer. Here we present data that reconcile the dual functions of BRCA2 as they relate to Rad51 assembly into active nuclear filaments associated with ssDNA. We show that the transition of the hBRCA2-Rad51 complex from an inactive form in undamaged cells to an active form in damaged cells is mediated by the DNA damage checkpoints Chk1 and Chk2. Both kinases can phosphorylate hBRCA2-CT on a threonine residue at position 3387 that is part of a Chk1/Chk2 consensus phosphorylation motif and is also part of a putative nuclear localization signal (NLS) indicating that this phosphorylation event may also participate in regulating hBRCA2's nuclear localization. Significantly, this phosphorylation event also regulates the binding of Rad51 to hBRCA2-CT. In undamaged cells, Rad51 binds at two sites within the hBRCA2 protein: the BRC repeat domain in the region encoded by exon 11 and the carboxy-terminal region encoded by exon 27. When cells are subjected to a DNA damaging agent, the binding of Rad51 to the BRC repeat domain is not affected. The Rad51 bound to the carboxy-terminal region, however, is released. Equally important is the observation that a mutant version of the carboxy-terminal domain in which threonine 3387 is mutated to alanine fails to release Rad51 suggesting that phosphorylation of threonine 3387 may act as a switch in the binding/release of Rad51 to the carboxy-terminal region of hBRCA2 following DNA damage. Overexpression of the mutant BRCA2-CT prevented Rad51 localization to sites of damage following challenge, stressing the role of T3387 phosphorylation in Rad51 recruitment to nuclear foci. In aggregate, these results suggest a mechanism involving the interaction between hBRCA2 and Rad51 that reconciles the two divergent functions described earlier.
In this model, hBRCA2 binds Rad51 at two separate domains that are individually regulated. The Rad51 protein bound to the BRC repeat domain is sequestered and kept in an inactive form and, when needed, is translocated to the carboxy-terminal domain by a mechanism that is still unclear. The Rad51 bound to the carboxy-terminal domain is the active form that is released in response to the damage to bind ssDNA and form nucleoprotein filaments. While Chk1 and Chk2 are clearly involved in the control of interactions between Figure 4 Retention of Rad51 binding to BRCA2 after UV treatment is dependent on Rad51 threonine 307, a Chk1-mediated phosphorylation site. Cells were cotransfected with myc-tagged wild type or T307A mutant Rad51 and with either GFP alone (lanes 1 and 2), GFP-BRCA2-CT (lanes 3 and 4) or with GFP-2R (lanes 5 and 6). After 24 h, cells were either treated with UV ( þ ) or left untreated (À) and after an additional 24 h cell lysates were subjected to immunoprecipitation with antibody to GFP. The proteins in the immunoprecipitates were fractionated by gel electrophoresis and probed by western blot with antibodies against Myc (top two panels) or GFP (lower two panels). hBRCA2 and Rad51, other proteins participate in this process. In particular, CDK1 has been shown to phosphorylate hBRCA2 at a site different than that phosphorylated by Chk1 and Chk2, and to regulate the interaction between BRCA2 and Rad51 during the cell cycle (Esashi et al., 2005) .
Chk1 is also essential for homologous recombination repair and Rad51 localization following replication block (Davies et al., 2001) . We have generated a mutant version of Rad51 carrying the previously described Chk1-mediated phosphorylation site (T307) and shown that mutation of threonine 307 to alanine does not affect the binding of Rad51 to the BRC repeat domain in presence or absence of damage. Like wild-type Rad51, this Rad51 mutant, however, does bind the carboxy-terminal domain of hBRCA2.
Recent evidence shows that purified BRCA BRC1-8 forms a ternary complex with Rad51 and DNA, and is capable of promoting Rad51-mediated strand exchange in vitro (Shivji et al., 2006) indicating that the BRC repeat domain may function to stimulate DNA recombination. As mentioned earlier, MEFs derived from mice homozygous for a BRCA2-CT deletion (lex1/lex2) have reduced viability, elevated hypersensitivity to DNA interstrand crosslinking agents and gross chromosomal instability (Donoho et al., 2003) . This cellular phenotype suggests an important role for this domain in regulating the function of BRCA2 in maintaining genomic integrity. It is clear that both domains within BRCA2 that bind Rad51 are essential for the full function of BRCA2 to facilitate recombination-mediated repair. Our model to explain the function of the dual Rad51 binding domains of hBRCA2 (Figure 6 ) proposes that Rad51 is sequestered by the exon 11-encoded BRC sequences in unperturbed cells. Following DNA damage, the sequestered Rad51 is transferred from the BRC repeats to the exons 26/27-encoded sequence by a mechanism that is not yet resolved. Understanding the mechanism underlying the cross-talk between these two domains of BRCA2 function and how Rad51 is translocated from one domain to the other will help clarify the role of BRCA2 in homology-mediated recombination repair.
Materials and methods
Cell culture, cell transfection and DNA damage treatment All cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat inactivated fetal bovine serum (FBS; Eurobio, Les Ulis, France), 2 mM glutamine, penicillin (100 U ml
À1
) and streptomycin (100 mg ml À1 ) in a humidified atmosphere containing 5% CO 2 at 37 1C. The cell lines used included HT1080 human fibrosarcoma cells, MEFs with wild-type BRCA2 or MEFs with exons 26 and 27 deleted that were immortalized with SV40largeT antigen (lex1/lex2 cells). Transfections were performed using Lipofectamine 2000 (Invitrogen, CA, USA) following the manufacturer's recommendations. For introduction of DNA damage, cells were either irradiated with 10 Gy of g-irradiation using a Gamma cell Irradiator (Cesium-137 source) or treated with 15 J m À2 UV-C light using a Stratalinker apparatus or treated with 16 mM of Adriamycin for 2 h.
Cell lysis, immunoprecipitation and western blotting Cells were harvested 24 h after transfection with vectors encoding GFP-tagged proteins and lysed in ice-cold lysis buffer (50 mM HEPES pH 7.0, 250 mM NaCl, 0.2% Nonidet P-40, 10% (v/v) glycerol, 1 mM NaVO 4 , 1 mM DTT) freshly supplemented with 1 mM phenylmethylsulphonyl fluoride (PMSF), 10 mg ml À1 aprotinin, pepstatin and leupeptin to inhibit proteolysis. Cell lysates were incubated on ice for 1 h with occasional mixing. Subsequently, 20 ml of protein A/G plus-agarose beads (Santa Cruz Biotechnology, CA, USA) were added and lysates were precleared by centrifugation for 5 min at 2000 g. The supernatant was incubated for 3 h at room temperature with 2 mg of GFP monoclonal antibody (Roche, IN, USA). Protein A/G plus-agarose beads were added and incubated for an additional 30 min. Recovered beads were washed four times, boiled for 5 min in sample buffer and fractionated by 10% SDS-PAGE, and immunoprecipitated proteins were analysed by western blot using Rad51 polyclonal antibody (Santa Cruz Biotechnology) or GFP monoclonal antibody (Roche).
Expression and purification of GFP and GST-fusion proteins GFP-Chk1 and GFP-Chk1 KD plasmids (a gift from Dr Yolanda Sanchez, Dartmouth College) were transfected into HT1080 cells. Both proteins were purified by immunoprecipitation from mammalian cell lysates using GFP monoclonal antibody (Roche). Purification of GST-fusion proteins was carried out using lysates of Escherichia coli BL21 cells that had been transformed with different plasmids. Cultures were grown at 37 1C to an A 600 of 0.8 and isopropyl-b-Dthiogalactopyranoside was added to a final concentration of 0.5 mM. After growing for an additional 3 h at 30 1C, cells were pelleted by centrifugation. Cell pellets were washed with phosphate-buffered saline (PBS) and were resuspended in STE buffer (100 mM NaCl, 10 mM Tris-HCl, pH 8.0, 1 mM EDTA) supplemented with 2 mM dithiothreitol (DTT), 1 mg ml À1 lysozyme and protease inhibitors (2 mM PMSF, 0.15 U ml À1 aprotinin, 20 mM leupeptin, 20 mM pepstatin). Cells were incubated on ice for 1 h with occasional mixing. Lysates were clarified by centrifugation (13 000 g for 15 min) and Triton X-100 was added to a final concentration of 2%. Proteins were precipitated with GSH-agarose beads (Sigma Chemical Co., MO, USA), washed three times with STE buffer, and eluted from GSH-agarose with 20 mM glutathione and 1 mM DTT in PBS.
In vitro kinase reactions Protein kinases were incubated with substrates at 37 1C for 1 h in 1 Â kinase buffer (30 mM HEPES pH 7.4, 10 mM MgCl 2 and 1 mM DTT) supplemented with 10 mM nonradioactive ATP and 10 mCi of [g] 32 P ATP (Amersham Pharmacia Biotech., NJ, USA). Kinase reactions were terminated by the addition of 6 Â SDS loading buffer, boiled for 10 min and fractionated by SDS-PAGE on 10% polyacrylamide gel.
Plasmid construction and site directed mutagenesis All of the GST and GFP fusion fragments of hBRCA2 were generated by PCR using a pcDNA3-hBRCA2 plasmid as template (a gift from JJ Chen, Mayo Clinic, Rochester). Site directed mutagenesis of the hBRCA2-CT and myc-Rad51 were performed using the QuikChange Site-Directed Mutagenesis Kit (Stratagene, CA, USA). The vector encoding SiRNA to Chk1 is a modified version of pSilencer 3.1-H1 hygro (Ambion, CA, USA), which expresses GFP protein and allows visualization of cells transfected with the SiRNA.
Confocal microscopy
MEFs of various genotypes were cultured on coverslips in DMEM, 10% FBS. Cells were washed with PBS, fixed with 4% paraformaldehyde and permeabilized for 10 min at room temperature with 0.2% Triton X-100 in PBS. After washing, coverslips were blocked with 10% horse serum, 1% bovine serum albumin, 0.02% NaN3 in 1% PBS. Cells were incubated with antibody against Rad51 (Santa Cruz Biotechnology) for 1 h at 37 1C. Coverslips were washed extensively with PBS and further incubated with 13.2 nM of the appropriate secondary antibody conjugated to Alexafluor 568 phalloidin (Molecular Probes, Eugene, OR, USA) in PBS for 30 min at room temperature, washed three times with PBS and mounted with Gelmount (Fisher Scientific, Pittsburgh, PA, USA). Cells were visualized with the use of a LSM 510 laser scanning confocal microscope (Zeiss, Oberkochen, Germany).
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